Brief: Renovorx Presenting Phase Iii Trial Interim Analysis Data At American Association For Cancer Research Annual Meeting In Florida
14/04/2023 14:56
April 14 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX PRESENTING PHASE III CLINICAL TRIAL INTERIM
ANALYSIS
DATA OF THE TIGER-PAC STUDY AT AMERICAN ASSOCIATION FOR CANCER
RESEARCH ANNUAL MEETING UNDERWAY IN ORLANDO, FLORIDA
Source text for Eikon: ID:nBw5X8rt7a
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies